125561 90%

The identifier appears across several distinct contexts, most notably as an FDA application number for the drug Kanuma and as an article identifier for a research paper on optimal nonparametric inference using deep neural networks. Pharmaceutical: FDA BLA 125561

Under number 125561 , written evidence was submitted by Mrs. C. Roche to the UK Parliament regarding the impact of screen time and "digital drugs" on children’s brains and ADHD . 125561

It is associated with a study on "Deep reinforcement learning for real-time energy dispatch in smart grids" published in the journal Applied Energy . 125561

In the medical field, is the Biologics License Application (BLA) number for Kanuma (sebelipase alfa) . 125561